Zurich Cantonal Bank
ACRS icon

Zurich Cantonal Bank’s Aclaris Therapeutics ACRS Stock Holding History

Zurich Cantonal Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.3K Buy
9,501
+4,495
+90% +$20K ﹤0.01% 2450
2026
Q1 		$18.8K Buy
+5,006
New +$16.9K ﹤0.01% 2459
2024
Q1 		– Sell
-43,784
Closed -$46K – 2708
2023
Q4 		$46K Buy
43,784
+23,467
+116% +$71.6K ﹤0.01% 2610
2023
Q3 		$139K Buy
20,317
+6,074
+43% +$51.9K ﹤0.01% 2187
2023
Q2 		$148K Buy
14,243
+4,484
+46% +$40.6K ﹤0.01% 2115
2023
Q1 		$79K Hold
9,759
– – ﹤0.01% 2421
2022
Q4 		$154K Buy
9,759
+2,258
+30% +$36.3K ﹤0.01% 1987
2022
Q3 		$118K Hold
7,501
– – ﹤0.01% 2086
2022
Q2 		$105K Hold
7,501
– – ﹤0.01% 2198
2022
Q1 		$129K Hold
7,501
– – ﹤0.01% 2152
2021
Q4 		$109K Buy
7,501
+4,290
+134% +$65K ﹤0.01% 2463
2021
Q3 		$58K Buy
+3,211
New +$51.5K ﹤0.01% 2574
2019
Q2 		– Sell
-1,818
Closed -$11K – 2614
2019
Q1 		$11K Hold
1,818
– – ﹤0.01% 2503
2018
Q4 		$13K Hold
1,818
– – ﹤0.01% 2521
2018
Q3 		$26K Hold
1,818
– – ﹤0.01% 2412
2018
Q2 		$36K Hold
1,818
– – ﹤0.01% 2285
2018
Q1 		$32K Hold
1,818
– – ﹤0.01% 2280
2017
Q4 		$45K Buy
1,818
+517
+40% +$12.6K ﹤0.01% 2131
2017
Q3 		$34K Hold
1,301
– – ﹤0.01% 2027
2017
Q2 		$35K Sell
1,301
-3,500
-73% -$95.2K ﹤0.01% 1970
2017
Q1 		$143K Buy
4,801
+3,500
+269% +$101K ﹤0.01% 1135
2016
Q4 		$35K Buy
+1,301
New +$33.2K ﹤0.01% 1932

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Zurich Cantonal Bank's ACRS Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Aclaris Therapeutics (ACRS) stake by 90% in Q2 2026, buying an estimated $20K and bringing the position to 9,501 shares worth $50.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

Zurich Cantonal Bank first reported a position in ACRS in Q4 2016 and has held it in 22 quarters since. The position peaked at $154K in Q4 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Zurich Cantonal Bank held 9,501 shares of Aclaris Therapeutics worth $50.3K as of Q2 2026.
  • Zurich Cantonal Bank bought 4,495 Aclaris Therapeutics shares in Q2 2026, an estimated $20K.
  • Aclaris Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2450 holding.
  • Zurich Cantonal Bank first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 22 quarters since.
  • Zurich Cantonal Bank's Aclaris Therapeutics position peaked at $154K in Q4 2022.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.